Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Globe Newswire•18/08/2026•08:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.